COA Results: View Full Report
Test Date
June 30, 2024
Purity
99.86%
Quantity
17.60mg
Anticipated Ship Date:
Next Business Day
Retatrutide For Sale
RETATRUTIDE 15mg
Retatrutide is a multi-receptor agonist that has shown significant promise in preclinical studies. This synthetic peptide targets several metabolic pathways by acting on multiple hormone receptors, including those involved in the regulation of glucose and lipid metabolism. Its unique structure allows for enhanced binding affinity and stability, which may contribute to its potent efficacy. Research indicates that retatrutide can modulate energy balance and influence metabolic rates, making it a compound of interest in studies focused on metabolic disorders. Further investigation into its pharmacokinetics and mechanism of action continues to reveal its potential applications in various metabolic processes.
$185.00
99 in stock
Frequently Asked Questions About Retatrutide
Retatrutide Research Chemical Information
Retatrutide Molecular Structure:
Sequence: YA1QGTFTSDYSIL2LDKK4AQA1AFIEYLLEGGPSSGAPPPS3
Molecular Formula: C223H343F3N46O70
Molecular Weight: 4845.44 g/mol
PubChem SID: 474492335
CAS Number: 2381089-83-2
Synonyms: LY-3437943, NOP2Y096GV
Retatrutide vs semaglutide?
Retatrutide and semaglutide are both drugs targeting metabolic pathways but differ in their mechanisms. Retatrutide is a multi-receptor agonist affecting various hormone receptors involved in glucose and lipid metabolism, offering broad therapeutic effects. Semaglutide, a GLP-1 receptor agonist, primarily targets the glucagon-like peptide-1 receptor, enhancing insulin secretion and slowing gastric emptying, effectively regulating blood glucose levels and treating type 2 diabetes and obesity.
Retatrutide half life?
Retatrutide has a long half-life, allowing for less frequent dosing. Its extended duration of action is due to its stable structure and strong receptor binding, which enhances its therapeutic potential in managing metabolic disorders. This prolonged half-life supports sustained metabolic effects, making it a promising candidate for further research and development.
Tirzepatide vs retatrutide?
Tirzepatide and retatrutide are investigational drugs targeting metabolic pathways but differ in their receptor profiles. Tirzepatide is a dual agonist for GLP-1 and GIP receptors, enhancing insulin secretion and improving glucose control. Retatrutide, a multi-receptor agonist, acts on multiple hormone receptors involved in glucose and lipid metabolism, potentially offering broader therapeutic effects. Both aim to treat metabolic disorders but through distinct mechanisms.
Retatrutide benefits?
Retatrutide offers several benefits due to its multi-receptor agonist activity. It targets multiple hormone receptors involved in glucose and lipid metabolism, potentially improving insulin sensitivity, reducing body weight, and enhancing lipid profiles. Its long half-life allows for less frequent dosing, providing sustained therapeutic effects and convenience. These benefits make retatrutide a promising candidate for treating metabolic disorders.
